Pau d'Arco: Antifungal, Antiviral, and Anti-Cancer…

Pau d'arco (Handroanthus impetiginosus, formerly Tabebuia impetiginosa) is the inner bark of a South American tree that has been used by indigenous Amazon communities to treat infections, inflammation, and cancer for centuries. Its primary active compounds — lapachol and beta-lapachone — have genuine antifungal, antiviral, and antiparasitic activity demonstrated in laboratory studies, with more limited but notable clinical evidence.

Lapachol and Beta-Lapachone

The primary active compounds are naphthoquinones: lapachol and its derivative beta-lapachone. These structurally related compounds work through similar mechanisms — they interfere with electron transport in mitochondria of target organisms (fungal, bacterial, viral, and cancer cells), generating reactive oxygen species that damage cellular membranes and DNA.

The selectivity of this toxicity — why lapachol damages pathogens and cancer cells more than healthy human cells — is attributed to the higher metabolic rate and different mitochondrial architecture of rapidly dividing cells and fungi. However, this selectivity is incomplete, which is why high-dose lapachol has toxicity in humans as well.

Antifungal Activity

Lapachol and beta-lapachone have demonstrated activity against multiple fungal pathogens in vitro, including Candida albicans, Aspergillus species, and dermatophytes. The minimum inhibitory concentrations (MICs) are in a range achievable with concentrated pau d'arco preparations, making antifungal activity the most biologically credible clinical application.

Case series and traditional use reports describe pau d'arco tea being used successfully for systemic and vaginal candidiasis. No well-controlled randomized trial has validated this application in humans, but the in vitro mechanism and traditional use pattern are reasonably consistent.

Antiviral Properties

Beta-lapachone has demonstrated antiviral activity in cell culture studies against RNA viruses including influenza, vesicular stomatitis virus, and some retroviruses. The mechanism involves inhibition of viral reverse transcriptase and interference with viral envelope synthesis. A preliminary human study suggested pau d'arco extract reduced herpes simplex recurrence frequency, though the study was uncontrolled.

Anti-Cancer Research

This is where pau d'arco's reputation expanded in the 1970s-80s, generating both excitement and controversy. Multiple in vitro studies and animal studies demonstrate that lapachol and beta-lapachone kill cancer cell lines at concentrations that minimally affect normal cells. The mechanism involves mitochondrial disruption, topoisomerase I and II inhibition, and induction of apoptosis through caspase activation.

Human clinical trials of lapachol for cancer were conducted in the 1970s at the US National Cancer Institute. The results were mixed — some patients showed tumor responses, but the dose required for clinical anti-tumor activity (1.5-2 g/day of pure lapachol) also produced significant toxicity including nausea, vomiting, and interference with vitamin K metabolism causing anticoagulation. At typical tea or supplement doses, tissue concentrations of lapachol are far below those needed for direct anti-cancer effects.

Anti-Inflammatory Effects

Beyond lapachol, pau d'arco bark contains xyloidone and other compounds with NF-kB inhibitory properties. Traditional use for arthritis and inflammatory conditions has some biological basis through this mechanism.

Safety and the Lapachol Toxicity Issue

This is the critical concern with pau d'arco. At high doses, lapachol interferes with vitamin K-dependent clotting factors, potentially causing serious bleeding. It can also cause nausea, vomiting, and anemia at high doses. Traditional pau d'arco tea contains relatively low lapachol concentrations — the pharmacologically active bark typically contains 2-7% lapachol — and this preparation has a long traditional safety record.

Concentrated extracts and capsules delivering multi-gram doses of bark extract may reach lapachol concentrations where these effects become clinically relevant. Avoid high-dose pau d'arco if taking anticoagulants (warfarin, heparin, newer anticoagulants).

Dosage

Traditional tea: 20-30 g of dried bark simmered in 1 liter of water for 20 minutes; drink 2-3 cups daily. Capsules: 500-1,500 mg/day of bark powder — avoid concentrated lapachol extracts at high doses. For antifungal or immune support applications, traditional tea preparations provide the breadth of bark phytochemicals with better safety profile than isolated lapachol.

FAQ

Can pau d'arco cure cancer? No. High-dose lapachol did show some tumor responses in early trials, but at doses causing significant toxicity. At typical supplement doses, tissue concentrations are far below those needed for direct anti-cancer activity. It may provide supportive benefits for cancer patients through anti-inflammatory and immune-supporting effects, but should never replace conventional cancer treatment.

Is pau d'arco safe to drink as tea daily? Traditional tea preparations appear to have an acceptable safety record at 2-3 cups daily in healthy adults. Avoid during pregnancy and with anticoagulant medications.

What health condition does pau d'arco have the most evidence for? Antifungal applications, particularly for candidiasis, have the most plausible and consistent evidence base.

Track your supplements in Optimize.

Pau d'Arco: Antifungal, Antiviral, and Anti-Cancer Evidence